KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
1 clinical trials · Condition
◉ Watch KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation (NCT07458347) | Kestrel Therapeutics, Inc. | 2026-04-21 |
Track KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) automatically
Every clearance here is in the API, with alerts when new ones post.